The emerging role of pharmacogenomics in the treatment of patients with heart failure.
Feldman
Arthur M
AM
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA. Arthur.feldman@mail.tju.edu
D000249:Adenosine Monophosphate / Q000235:genetics; D000818:Animals; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics; D005838:Genotype; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D009154:Mutation; D019001:Nitric Oxide Synthase / Q000235:genetics; D052250:Nitric Oxide Synthase Type III; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D010597:Pharmacogenetics; D010641:Phenotype; D011943:Receptors, Adrenergic, beta / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D011943:Receptors, Adrenergic, beta; D014409:Tumor Necrosis Factor-alpha; D000249:Adenosine Monophosphate; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D019405:Cytochrome P-450 CYP11B2; D007703:Peptidyl-Dipeptidase A